Additional response criteria and updates
| MR in patients with relapsed refractory myeloma adopted from the EBMT criteria8 . | Immunophenotypic CR . | Molecular CR . |
|---|---|---|
| ≥ 25% but ≤ 49% reduction of serum M protein and reduction in 24-hour urine M-protein by 50%-89% | Stringent CR plus | CR plus negative ASO-PCR, sensitivity 10−5 |
| In addition to the above criteria, if present at baseline, 25%-49% reduction in the size of soft tissue plasmacytomas is also required | Absence of phenotypically aberrant PCs (clonal) in BM with a minimum of 1 million total BM cells analyzed by multiparametric flow cytometry (with > 4 colors) | |
| No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response) |
| MR in patients with relapsed refractory myeloma adopted from the EBMT criteria8 . | Immunophenotypic CR . | Molecular CR . |
|---|---|---|
| ≥ 25% but ≤ 49% reduction of serum M protein and reduction in 24-hour urine M-protein by 50%-89% | Stringent CR plus | CR plus negative ASO-PCR, sensitivity 10−5 |
| In addition to the above criteria, if present at baseline, 25%-49% reduction in the size of soft tissue plasmacytomas is also required | Absence of phenotypically aberrant PCs (clonal) in BM with a minimum of 1 million total BM cells analyzed by multiparametric flow cytometry (with > 4 colors) | |
| No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response) |
EBMT indicates European Group for Blood and Marrow Transplantation; PCs, plasma cells; and ASO-PCR, allele-specific oligonucleotide polymerase chain reaction.